LKLaura Klenow

Laura Klenow

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laura Klenow has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Elizabeth M Coyle

    Division of Viral Products Center for Biologics Evaluation and Research (CBER) FDA, Silver Spring MD USA

    1 shared publication
  • Hana Golding

    Division of Viral Products Center for Biologics Evaluation and Research (CBER) FDA, Silver Spring MD USA

    1 shared publication
  • Hongquan Wan

    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA

    1 shared publication
  • Jeehyun Lee

    Division of Viral Products Center for Biologics Evaluation and Research (CBER) FDA, Silver Spring MD USA

    1 shared publication
  • Jin Gao

    Division of Viral Products, Center for Biologics Evaluation and Research Food and Drug Administration Silver Spring, Maryland 20993 United States

    1 shared publication
  • Juanjie Tang

    Division of Viral Products Center for Biologics Evaluation and Research (CBER) FDA, Silver Spring MD USA

    1 shared publication

Latest Publications

  • Open Access

    Antigenic comparison of the neuraminidases from recent influenza A vaccine viruses and 2019–2020 circulating strains

    by Jin Gao, Xing Li, Laura Klenow, Tahir Malik, Hongquan Wan, Zhiping Ye, Robert Daniels

    Although viral-based influenza vaccines contain neuraminidase (NA or N) antigens from the recommended seasonal strains, NA is not extensively evaluated like hemagglutinin (H) during the strain selection process. Here, we compared the antigenicity of NAs from recently recommended H1N1 (2010–2021 seasons) and H3N2 (2015–2021 seasons) vaccine strains and viruses that circulated between September 2019 and December 2020. The antigenicity was evaluated by measuring NA ferret antisera titers that provide 50% inhibition of NA activity in an enzyme-linked lectin assay. Our results show that NAs from circulating H1N1 viruses and vaccine strains for the 2017–2021 seasons are all antigenically similar and distinct from the NA in the H1N1 strain recommended for the 2010–2017 seasons. Changes in N1 antigenicity were attributed to the accumulation of substitutions over time, especially the loss of an N-linked glycosylation site (Asn386) in current N1s. The NAs from circulating H3N2 viruses and the 2020–2021 vaccine strains showed similar antigenicity that varied across the N2s in the 2016–2020 vaccine strains and was distinct from the N2 in the 2015–2016 vaccine strain. These data suggest that the recent N1 antigenicity has remained similar since the loss of the head domain N-linked glycosylation site, whereas N2 antigenicity has changed more incrementally each season.


  • Open Access

    Protective antigenic sites identified in respiratory syncytial virus fusion protein reveals importance of p27 domain

    by Jeehyun Lee, Youri Lee, Laura Klenow, Elizabeth M Coyle, Juanjie Tang, Supriya Ravichandran, Hana Golding, Surender Khurana

    Respiratory syncytial virus (RSV) vaccines primarily focused on surface fusion (F) protein are under development. Therefore, to identify RSV‐F protective epitopes, we evaluated 14 antigenic sites recognized following primary human RSV infection. BALB/c mice were vaccinated with F peptides, F proteins, or RSV‐A2, followed by rA2‐Line19F challenge. F peptides generated binding antibodies with minimal in vitro neutralization titers. However, several F peptides (including Site II) reduced lung viral loads and lung pathology scores in animals, suggesting partial protection from RSV disease. Interestingly, animals vaccinated with peptides (aa 101–121 and 110–136) spanning the F‐p27 sequence, which is only present in unprocessed F0 protein, showed control of viral loads with significantly reduced pathology compared with mock‐vaccinated controls. Furthermore, we observed F‐p27 expression on the surface of RSV‐infected cells as well as lungs from RSV‐infected mice. The anti‐p27 antibodies demonstrated antibody‐dependent cellular cytotoxicity (ADCC) of RSV‐infected A549 cells. These findings suggest that p27‐mediated immune response may play a role in control of RSV disease in vivo, and F‐p27 should be considered for inclusion in an effective RSV vaccine.